Genzyme-total-orphan-drugs-rare-disease

Genzyme: The men behind the giant

In Partnering & Investment by CameronLeave a Comment

Genzyme has lead the way in orphan drug strategy since its founding in 1981. After its acquisition by Sonofi in 2011, Genzyme has become the world leader in rare disease and multiple sclerosis research. Bringing in sales of €2.142b in 2013 Genzyme has a presence in over 40 countries across the world.

Now find out who has been holding Genzyme aloft in their position as the industry leader in rare diseases.

Next Page >

Leave a Comment

Current ye@r *